Compare CHD & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | DGX |
|---|---|---|
| Founded | 1846 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 20.5B |
| IPO Year | N/A | 1996 |
| Metric | CHD | DGX |
|---|---|---|
| Price | $81.94 | $182.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | $101.43 | ★ $194.07 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 10-31-2025 | 10-21-2025 |
| Dividend Yield | 1.45% | ★ 1.76% |
| EPS Growth | ★ 42.14 | 14.49 |
| EPS | 3.17 | ★ 8.51 |
| Revenue | $6,141,000,000.00 | ★ $10,850,000,000.00 |
| Revenue This Year | $2.52 | $12.37 |
| Revenue Next Year | $4.02 | $3.52 |
| P/E Ratio | $25.75 | ★ $21.35 |
| Revenue Growth | 1.45 | ★ 13.74 |
| 52 Week Low | $81.33 | $148.70 |
| 52 Week High | $116.46 | $197.55 |
| Indicator | CHD | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 43.95 |
| Support Level | $83.37 | $184.18 |
| Resistance Level | $84.90 | $185.12 |
| Average True Range (ATR) | 1.44 | 3.09 |
| MACD | 0.03 | -0.85 |
| Stochastic Oscillator | 4.72 | 6.46 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which together with Arm & Hammer constitute around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.